Skip to main content

Table 3 Change in variables in obese with NAFLD children treated with GH vs control group for 3 months

From: Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease

Variable

rhGH group

(n = 22)

control group

(n = 22)

p value

BMI SDS

2.37 ± 0.69

2.66 ± 0.54

0.138

IGF-1(ng/ml)

473.36 ± 159.12

355.86 ± 126.98

0.01*

CRP(mg/L)

1.24 ± 0.80

2.07 ± 1.14

0.008*

ALT(U/L)

18.25(13.50,27.75)

21.00(16.75, 42.25)

0.113â–²

AST(U/L)

21.50(19.88,28.75)

23.00(20.00, 30.50)

0.430â–²

GGT(U/L)

14.00(12.75,17.75)

24.00(20.00, 33.25)

 < 0.001*▲

TC(mmol/L)

3.99 ± 0.59

4.15 ± 0.76

0.432

HDL-C (mmol/L)

1.41 ± 0.30

1.12 ± 0.20

0.001*

LDL-C (mmol/L)

2.17 ± 0.42

2.49 ± 0.53

0.033*

TG(mmol/L)

0.90(0.71, 1.52)

1.05(0.82, 1.38)

0.578#

UA(μmol/L)

423.96 ± 97.51

376.64 ± 78.65

0.084

Insulin(uIU/mL)

31.16(21.28,36.75)

17.04(14.43, 28.46)

0.086#

FBG(mmol/L)

5.34 ± 0.31

5.25 ± 0.40

0.393

HOMA-IR

7.34(5.16, 8.76)

3.99(3.02, 6.94)

0.078#

HbA1c (%)

5.62 ± 0.35

5.62 ± 0.30

1#

  1. # p value reported for log transformed values, but values in the table represent as the median (interquartile range) ▲Mann–Whitney U test
  2. * p < 0.05
  3. Abbreviations: BMI SDS Body mass index standard deviation scores, IGF-1 Insulin-like growth factor 1, CRP C reactive protein, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, GH Growth hormone, TC Total cholesterol, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, TG Triglycerides, UA Uric acid, FBG Fasting blood glucose, HOMA-IR Homeostasis model assessment of IR, HbA1c Glycosylated haemoglobin